Jpmorgan Chase & CO Oric Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 33,972 shares of ORIC stock, worth $348,213. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,972

Previous 31,801 6.83%

Holding current value

$348,213

Previous $437,000 45.08%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$6.63 - $12.93 $14,393 - $28,071	2,171 Added 6.83%	33,972 $240,000
Q1 2024 May 10, 2024	SELL	$8.04 - $16.03 $51,246 - $102,175	-6,374 Reduced 16.7%	31,801 $437,000
Q4 2023 Feb 12, 2024	BUY	$5.41 - $9.43 $61,701 - $107,549	11,405 Added 42.6%	38,175 $351,000
Q3 2023 Nov 14, 2023	SELL	$6.05 - $9.28 $25,736 - $39,477	-4,254 Reduced 13.71%	26,770 $161,000
Q2 2023 Aug 11, 2023	BUY	$4.95 - $8.4 $147,826 - $250,857	29,864 Added 2574.48%	31,024 $240,000
Q1 2023 May 11, 2023	BUY	$4.26 - $6.75 $1,704 - $2,700	400 Added 52.63%	1,160 $6,000
Q4 2022 Feb 13, 2023	SELL	$2.41 - $5.89 $31,291 - $76,475	-12,984 Reduced 94.47%	760 $4,000
Q3 2022 Nov 14, 2022	BUY	$3.15 - $5.24 $24,639 - $40,987	7,822 Added 132.08%	13,744 $44,000
Q2 2022 Aug 11, 2022	SELL	$2.7 - $7.07 $37,076 - $97,085	-13,732 Reduced 69.87%	5,922 $27,000
Q1 2022 May 11, 2022	BUY	$4.54 - $16.1 $17,224 - $61,083	3,794 Added 23.92%	19,654 $105,000
Q4 2021 Feb 10, 2022	SELL	$12.01 - $20.3 $73,020 - $123,424	-6,080 Reduced 27.71%	15,860 $233,000
Q3 2021 Nov 12, 2021	BUY	$15.9 - $25.22 $348,846 - $553,326	21,940 New	21,940 $459,000

Others Institutions Holding ORIC

# of Institutions

112

Shares Held

63.1M

Call Options Held

Put Options Held

View Full List

About Oric Pharmaceuticals, Inc.

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $406M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

More about ORIC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Oric Pharmaceuticals, Inc. Transaction History